Literature DB >> 33947034

In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells.

Sherif Aly El-Kafrawy1,2, Sayed Sartaj Sohrab1,2, Zeenat Mirza2,3, Ahmed M Hassan1, Fatima Alsaqaf1, Esam Ibraheem Azhar1,2.   

Abstract

MERS-CoV was identified for the first time in Jeddah, Saudi Arabia in 2012 in a hospitalized patient. This virus subsequently spread to 27 countries with a total of 939 deaths and 2586 confirmed cases and now has become a serious concern globally. Camels are well known for the transmission of the virus to the human population. In this report, we have discussed the prediction, designing, and evaluation of potential siRNA targeting the ORF1ab gene for the inhibition of MERS-CoV replication. The online software, siDirect 2.0 was used to predict and design the siRNAs, their secondary structure and their target accessibility. ORF1ab gene folding was performed by RNAxs and RNAfold software. A total of twenty-one siRNAs were selected from 462 siRNAs according to their scoring and specificity. siRNAs were evaluated in vitro for their cytotoxicity and antiviral efficacy in Huh7 cell line. No significant cytotoxicity was observed for all siRNAs in Huh7 cells. The in vitro study showed the inhibition of viral replication by three siRNAs. The data generated in this study provide preliminary and encouraging information to evaluate the siRNAs separately as well as in combination against MERS-CoV replication in other cell lines. The prediction of siRNAs using online software resulted in the filtration and selection of potential siRNAs with high accuracy and strength. This computational approach resulted in three effective siRNAs that can be taken further to in vivo animal studies and can be used to develop safe and effective antiviral therapies for other prevalent disease-causing viruses.

Entities:  

Keywords:  Huh7cells; MERS-CoV; Saudi Arabia; designing; in silico prediction; siRNAs

Mesh:

Substances:

Year:  2021        PMID: 33947034     DOI: 10.3390/molecules26092610

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  56 in total

1.  siRNAs can function as miRNAs.

Authors:  John G Doench; Christian P Petersen; Phillip A Sharp
Journal:  Genes Dev       Date:  2003-02-15       Impact factor: 11.361

2.  Effects of siRNA-mediated suppression of HPV-11 L1 expression on the proliferation and apoptosis of vaginal epithelial cells.

Authors:  Juan Zeng; Shumei Yang; Xiaorui Wang; Yan Gao; Mei Zhang
Journal:  Exp Ther Med       Date:  2017-02-10       Impact factor: 2.447

Review 3.  Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.

Authors:  Sayed Sartaj Sohrab; Sherif Aly El-Kafrawy; Zeenat Mirza; Mohammad Amjad Kamal; Esam Ibraheem Azhar
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 4.  Recent developments in antivirals against hepatitis B virus.

Authors:  Ya-Juan Wang; Li Yang; Jian-Ping Zuo
Journal:  Virus Res       Date:  2015-12-28       Impact factor: 3.303

5.  Detailed interrogation of trypanosome cell biology via differential organelle staining and automated image analysis.

Authors:  Richard J Wheeler; Keith Gull; Eva Gluenz
Journal:  BMC Biol       Date:  2012-01-03       Impact factor: 7.431

Review 6.  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus.

Authors:  Chean Yeah Yong; Hui Kian Ong; Swee Keong Yeap; Kok Lian Ho; Wen Siang Tan
Journal:  Front Microbiol       Date:  2019-08-02       Impact factor: 5.640

7.  A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.

Authors:  Anwar M Hashem; Abdullah Algaissi; Anurodh Shankar Agrawal; Sawsan S Al-Amri; Rowa Y Alhabbab; Sayed S Sohrab; Abdulrahman S Almasoud; Naif Khalaf Alharbi; Bi-Hung Peng; Marsha Russell; Xuguang Li; Chien-Te K Tseng
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

8.  Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Authors:  Pedro M Folegatti; Mustapha Bittaye; Amy Flaxman; Fernando Ramos Lopez; Duncan Bellamy; Alexandra Kupke; Catherine Mair; Rebecca Makinson; Jonathan Sheridan; Cornelius Rohde; Sandro Halwe; Yuji Jeong; Young-Shin Park; Jae-Ouk Kim; Manki Song; Amy Boyd; Nguyen Tran; Daniel Silman; Ian Poulton; Mehreen Datoo; Julia Marshall; Yrene Themistocleous; Alison Lawrie; Rachel Roberts; Eleanor Berrie; Stephan Becker; Teresa Lambe; Adrian Hill; Katie Ewer; Sarah Gilbert
Journal:  Lancet Infect Dis       Date:  2020-04-21       Impact factor: 25.071

9.  Efficacy Analysis of Combinatorial siRNAs against HIV Derived from One Double Hairpin RNA Precursor.

Authors:  Chang Liu; Zhipin Liang; Xiaohong Kong
Journal:  Front Microbiol       Date:  2017-08-29       Impact factor: 5.640

10.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.

Authors:  Abdullah Assiri; Jaffar A Al-Tawfiq; Abdullah A Al-Rabeeah; Fahad A Al-Rabiah; Sami Al-Hajjar; Ali Al-Barrak; Hesham Flemban; Wafa N Al-Nassir; Hanan H Balkhy; Rafat F Al-Hakeem; Hatem Q Makhdoom; Alimuddin I Zumla; Ziad A Memish
Journal:  Lancet Infect Dis       Date:  2013-07-26       Impact factor: 25.071

View more
  3 in total

1.  Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells.

Authors:  Sayed Sartaj Sohrab; Sherif Aly El-Kafrawy; Esam Ibraheem Azhar
Journal:  J King Saud Univ Sci       Date:  2022-03-16

Review 2.  Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.

Authors:  Yuan Zhang; Juhura G Almazi; Hui Xin Ong; Matt D Johansen; Scott Ledger; Daniela Traini; Philip M Hansbro; Anthony D Kelleher; Chantelle L Ahlenstiel
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

3.  In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells.

Authors:  Sayed Sartaj Sohrab; Sherif Aly El-Kafrawy; Esam Ibraheem Azhar
Journal:  J King Saud Univ Sci       Date:  2022-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.